Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Virpax Pharmaceuticals Inc (VRPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VRPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.61% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.03M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 454807 | Beta 1.09 | 52 Weeks Range 1.08 - 104.28 | Updated Date 03/30/2025 |
52 Weeks Range 1.08 - 104.28 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -91.42% | Return on Equity (TTM) -362.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 77348 | Price to Sales(TTM) - |
Enterprise Value 77348 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.05 | Shares Outstanding 4887580 | Shares Floating 4586311 |
Shares Outstanding 4887580 | Shares Floating 4586311 | ||
Percent Insiders 2.57 | Percent Institutions 0.04 |
Analyst Ratings
Rating 3 | Target Price 3 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Virpax Pharmaceuticals Inc
Company Overview
History and Background
Virpax Pharmaceuticals Inc. is a biotechnology company focused on developing pharmaceutical product candidates for pain management, CNS diseases, and anti-viral indications. Founded in 2003, Virpax has focused on innovative delivery systems and targets unmet medical needs.
Core Business Areas
- Pain Management: Developing non-opioid pain management solutions using its proprietary technology.
- CNS Diseases: Researching and developing treatments for central nervous system disorders.
- Anti-Viral: Developing novel antiviral therapies to combat infectious diseases.
Leadership and Structure
The leadership team includes key executives in research, development, and finance. The organizational structure is typical of a development-stage biotechnology company.
Top Products and Market Share
Key Offerings
- Enveltau2122: Enveltau2122 is a product candidate being developed for the management of chronic pain and acute pain, including post-operative pain and chronic neuropathic pain. There is no Market Share Data yet. Competitors include companies offering opioid and non-opioid pain medications.
- Epolocu2122: Epolocu2122 is a product candidate for the treatment of certain types of viral infections. There is no Market Share Data yet. Competitors include companies developing antiviral medications.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Current market trends include a focus on personalized medicine and innovative drug delivery systems.
Positioning
Virpax is positioned as a specialty pharmaceutical company focusing on developing innovative treatments for unmet medical needs. Its competitive advantage lies in its proprietary drug delivery technologies.
Total Addressable Market (TAM)
TAM is significant across pain management and antiviral therapeutics. Virpax's positioning allows it to target niche markets within these larger sectors.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage pipeline
- Dependence on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- ABBV
- LLY
Competitive Landscape
Virpax faces intense competition from established pharmaceutical companies with significantly greater resources. Its competitive advantage lies in its novel drug delivery technologies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Virpax's growth has been driven by progress in its clinical trials and securing funding.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely given the inherent risks of the biotechnology industry.
Recent Initiatives: Recent initiatives include advancing its lead product candidates through clinical development and exploring potential partnerships.
Summary
Virpax Pharmaceuticals Inc. is a development-stage company with a focus on pain management and antiviral solutions. Its proprietary technology and pipeline offer potential, but success hinges on clinical trial outcomes and funding. The company faces significant competition and regulatory hurdles, requiring strategic partnerships and efficient execution to thrive.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry databases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data accuracy is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Virpax Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Berwyn, PA, United States | ||
IPO Launch date 2021-02-17 | CEO & Chairman Mr. Jatinder Dhaliwal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.virpaxpharma.com |
Full time employees 2 | Website https://www.virpaxpharma.com | ||
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.